Dr. Lee on Immunotherapy’s Future in RCC – OncLive
OncLive |
Dr. Lee on Immunotherapy's Future in RCC
OncLive … may be very important. These include potential combinations with immunotherapy plus VEGF-targeted therapy. Or, there may be a development of new pathways that might be significant, now that researchers better understand the genetics of kidney cancer. |
